{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:23Z","timestamp":1791903323685,"version":"4.3.4"},"reference-count":24,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)\u2013like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell\u2013associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P&amp;lt; .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse\/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P&amp;lt; .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P&amp;lt; .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19\u2212 relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P&amp;lt; .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19\u2212 relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P&amp;lt; .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19\u2212 relapse and nonrelapse mortality as key outcome drivers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020511","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:04:14Z","timestamp":1784340254000},"page":"6422-6434","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["HLH-like syndromes associate with increased risk of death and CD19\u2212 relapse after CAR T in pediatric B-ALL"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL"},{"name":"2Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyang","family":"Kwon","sequence":"additional","affiliation":[{"name":"3Buehler Center for Health Policy and Economics, Northwestern Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Naik","sequence":"additional","affiliation":[{"name":"4Department of Bone Marrow Transplantation and Cell Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa A.","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado School of Medicine, Children\u2019s Hospital of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Llaurador","family":"Caraballo","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Center for Cell and Gene Therapy, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7434-6747","authenticated-orcid":false,"given":"L. Nelson","family":"Sanchez-Pinto","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, IL"},{"name":"7Division of Critical Care, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL"},{"name":"8Department of Preventive Medicine, Northwestern Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6706","authenticated-orcid":false,"given":"Aimee","family":"Talleur","sequence":"additional","affiliation":[{"name":"4Department of Bone Marrow Transplantation and Cell Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Zeng","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL"},{"name":"2Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Baggott","sequence":"additional","affiliation":[{"name":"9Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-0490","authenticated-orcid":false,"given":"Anant","family":"Vatsayan","sequence":"additional","affiliation":[{"name":"10Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Children\u2019s National Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado School of Medicine, Children\u2019s Hospital of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-3087","authenticated-orcid":false,"given":"Snehit","family":"Prabhu","sequence":"additional","affiliation":[{"name":"9Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-9883","authenticated-orcid":false,"given":"Jenna","family":"Rossoff","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL"},{"name":"2Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Pacenta","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, University of Texas Southwestern Medical Center\/Children\u2019s Health, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Phillips","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, University of Cincinnati, Cincinnati, OH"},{"name":"13Cancer and Blood Disease Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-An","family":"Talano","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children\u2019s Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children\u2019s Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Douglass","family":"Myers","sequence":"additional","affiliation":[{"name":"4Department of Bone Marrow Transplantation and Cell Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Karras","sequence":"additional","affiliation":[{"name":"15Department of Pediatrics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-1683","authenticated-orcid":false,"given":"Challice","family":"Bonifant","sequence":"additional","affiliation":[{"name":"16Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"17Division of Pediatric Hematology\/Oncology and Bone Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Emory University and Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[{"name":"18Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1594","authenticated-orcid":false,"given":"Lena","family":"Winestone","sequence":"additional","affiliation":[{"name":"19Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Krupski","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, University of Cincinnati, Cincinnati, OH"},{"name":"13Cancer and Blood Disease Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-8456","authenticated-orcid":false,"given":"Amy K.","family":"Keating","sequence":"additional","affiliation":[{"name":"20Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Baumeister","sequence":"additional","affiliation":[{"name":"20Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Egeler","sequence":"additional","affiliation":[{"name":"9Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-4623","authenticated-orcid":false,"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[{"name":"19Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[{"name":"21Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"9Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"},{"name":"22Parker Institute for Cancer Immunotherapy, San Francisco, CA"},{"name":"23Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"},{"name":"24Division of Blood and Marrow Transplantation and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"25Weill West Coast Cancer Hub, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"John","sequence":"additional","affiliation":[{"name":"26Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center\/Children\u2019s Health, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[{"name":"27Division of Oncology, Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-3200","authenticated-orcid":false,"given":"Rebecca","family":"Gardner","sequence":"additional","affiliation":[{"name":"28Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7597","authenticated-orcid":false,"given":"Liora M.","family":"Schultz","sequence":"additional","affiliation":[{"name":"18Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2026101310434883200_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026101310434883200_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2026101310434883200_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026101310434883200_bib4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2026101310434883200_bib5","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2026101310434883200_bib6","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026101310434883200_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"2026101310434883200_bib8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026101310434883200_bib9","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2026101310434883200_bib10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2026101310434883200_bib11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026101310434883200_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026101310434883200_bib13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2026101310434883200_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026101310434883200_bib15","doi-asserted-by":"crossref","first-page":"e011549","DOI":"10.1136\/jitc-2025-011549","article-title":"CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy","volume":"13","author":"Myers","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2026101310434883200_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"issue":"10","key":"2026101310434883200_bib17","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2026101310434883200_bib18","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1182\/bloodadvances.2025016824","article-title":"Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel","volume":"9","author":"Naik","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026101310434883200_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026101310434883200_bib20","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"2026101310434883200_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"2026101310434883200_bib22","doi-asserted-by":"crossref","first-page":"e012401","DOI":"10.1136\/jitc-2025-012401","article-title":"Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy","volume":"13","author":"Strati","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2026101310434883200_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2022-166322","article-title":"Patients with deleterious germline variants in STXBP2 develop toxicity after CAR-T cell therapy with axicabtagene ciloleucel","volume":"140","author":"Leick","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026101310434883200_bib24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6422\/2590648\/blooda_adv-2026-020511-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6422\/2590648\/blooda_adv-2026-020511-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:55Z","timestamp":1791902635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6422\/569762\/HLH-like-syndromes-associate-with-increased-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020511","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,24]]}}}